Pengaruh Komorbid Hipertensi terhadap Severitas Pasien yang Terinfeksi Covid 19

Arif Gunawan, Kartika Prahasanti, M. Reza Utama

Abstract


COVID 19 saat ini merupakan salah satu masalah yang ramai diperbincangkan oleh seluruh masyarakat di dunia. Penyebaran virus ini sangat cepat bahkan hampir seluruh negara di dunia merasakan dampak dari virus ini. Virus ini sangat berbahaya apabila menginfeksi orang yang memiliki daya tahan tubuh yang rendah dan dipengaruhi usai, jenis kelamin laki-laki, perokok aktif. dan beberapa penyakit komorbid diantaranya adalah hipertensi dan diabetes mellitus. Pada pasien hipertensi, diabetes melitus, dan perokok, diduga adanya peningkatan ekspresi reseptor ACE2. Hipertensi dapat mejadi faktor risiko dari COVID 19, hal ini dikaitkan dengan penggunaan obat anti hipertensi seperti obat angiotensin mengkonversi enzim inhibitor (ACEI) dan angiotensin reseptor blockers (ARBs), karena penggunaan obat ini bisa saja meregulasi reseptor ACE2 bahkan memperparah COVID 19, namun hal ini belum terbukti secara jelas, karena beberapa penelitian juga menjelaskan bahwa penggunaan obat ini tidak mempengaruhi tingkat keparahan COVID 19.


Keywords


hipertensi, COVID 19, epidemiologi, etiologi, gambaran klisis, ACEI, ARB, kardiovaskular

References


Burhan E, Isbaniah F, Susanto AD, et al. PNEUMONIA COVID_19 DIAGNOSIS & PENATALAKSANAAN DI INDONESIA. Vol 55.; 2020. doi:10.1331/JAPhA.2015.14093

Wang Y, Wang Y, Chen Y, Qin Q. Unique epidemiological and clinical features of the emerging 2019 novel coronavirus pneumonia (COVID-19) implicate special control measures. J Med Virol. 2020;92(6):568-576. doi:10.1002/jmv.25748

Wu P, Hao X, Lau EHY, et al. Real-time tentative assessment of the epidemiological characteristics of novel coronavirus infections in Wuhan, China, as at 22 January 2020. Eurosurveillance. 2020;25(3):1-6. doi:10.2807/1560-7917.ES.2020.25.3.2000044

Wang W, Tang J, Wei F. Updated understanding of the outbreak of 2019 novel coronavirus (2019-nCoV) in Wuhan, China. J Med Virol. 2020;92(4):441-447. doi:10.1002/jmv.25689

Forum SP. KESIAPAN KEMENKES DALAM MENGHADAPI OUTBREAK NOVEL CORONAVIRUS ( 2019-nCoV ). 2020.

Sylvestris A. Hipertensi Dan Retinopati Hipertensi. Saintika Med. 2017;10(1):1. doi:10.22219/sm.v10i1.4142

Kreutz R, Algharably EAEH, Azizi M, et al. Hypertension, the renin-angiotensin system, and` the risk of lower respiratory tract infections and lung injury: implications for COVID-19. Cardiovasc Res. 2020:1-12. doi:10.1093/cvr/cvaa097

Guan W, Ni Z, Hu Y, et al. Clinical characteristics of coronavirus disease 2019 in China. N Engl J Med. 2020;382(18):1708-1720. doi:10.1056/NEJMoa2002032

Chang T, Wu J, Chang L. Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID- research that is available on the COVID-19 resource centre - including this ScienceDirect Clinical characteris. J Formos Med Assoc. 2020;(January).

Antonia Anna Lukito, Eka Harmeiwaty NMH. hipertensi event_Update_konsensus_2019123191. 2019:118. http://www.inash.or.id/upload/event/event_Update_konsensus_2019123191.pdf.

Untario E. Hubungan Merokok Dengan Kejadian Hipertensi pada Wanita Lansia. Keperawatan. 2017;11(11):40-47.

Kementerian Kesehatan, Indonesia R. Hipertensi Penyakit Paling Banyak Diidap Masyarakat. Kementeri Kesehat RI Sekr r Jenderal Rencana Strateg Kementeri Kesehat Tahun Rencana Strateg Kementeri Kesehat Tahun. 2019:248. doi:351.077 Ind r

Dafriani P. Pendekatan Herbal Dalam Mengatasi Hipertensi. CVBerkah Prima: Padang. 2019:1-33.

Rampengan SH. Hipertensi Resisten Resistant Hypertension. J Kedokt Yars. 2015;23(2):114-127. https://media.neliti.com/media/publications/104793-ID-hipertensi-resisten.pdf.

Weber MA, Schiffrin EL, White WB, et al. Clinical Practice Guidelines for the Management of Hypertension in the Community A Statement by the American Society of Hypertension and the International Society of Hypertension. 2014;16(1). doi:10.1111/jch.12237

Li G, Hu R, Gu X. A close-up on COVID-19 and cardiovascular diseases. Nutr Metab Cardiovasc Dis. 2020. doi:10.1016/j.numecd.2020.04.001

World Health Organization (WHO). Report of the WHO-China Joint Mission on Coronavirus Disease 2019 (COVID-19). WHO-China Jt Mission Coronavirus Dis 2019. 2020;1(February):40. https://www.who.int/docs/default-source/coronaviruse/who-china-joint-mission-on-covid-19-final-report.pdf.

Tim Kerja Kementerian Dalam Negeri. Pedoman Umum Menghadapi Pandemi Covid-19 Bagi Pemerintah Daerah : Pencegahan, Pengendalian, Diagnosis dan Manajemen. J Chem Inf Model. 2013;53(9):1689-1699. doi:10.1017/CBO9781107415324.004

Kemenkes RI. Pedoman Pencegahan dan Pengendalian Coronavirus Disease (COVID-19). Germas. 2020:0-115.

Ke H. According to Hubei Science and Technology Press. 2019.

Fehr AR, Perlman S. Chapter 1 Coronaviruses : An Overview of Their Replication and Pathogenesis. 2015;1282(1). doi:10.1007/978-1-4939-2438-7

Susilo A, Rumende CM, Pitoyo CW, et al. Coronavirus Disease 2019 : Tinjauan Literatur Terkini Coronavirus Disease 2019 : Review of Current Literatures. J Penyakit Dalam Indones. 2020;7(1):45-67.

Letko M, Marzi A, Munster V. Functional assessment of cell entry and receptor usage for SARS-CoV-2 and other lineage B betacoronaviruses. Nat Microbiol. 2020;5(4):562-569. doi:10.1038/s41564-020-0688-y

Sun P, Lu X, Xu C, Sun W, Pan B. Understanding of COVID-19 based on current evidence. J Med Virol. 2020;92(6):548-551. doi:10.1002/jmv.25722

Firdaus I, Sukmawan R, Santoso A, Juzar DA. PANDUAN DIAGNOSIS DAN TATALAKSANA PENYAKIT KARDIOVASKULAR PADA PANDEMI COVID-19. 2020;3(2):54-67. http://repositorio.unan.edu.ni/2986/1/5624.pdf.

Tignanelli CJ, Ingraham NE, Sparks MA, et al. Antihypertensive drugs and risk of COVID-19? Lancet Respir Med. 2020;8(5):e30-e31. doi:10.1016/S2213-2600(20)30153-3

Lippi G, Wong J, Henry BM. Hypertension in patients with coronavirus disease 2019 (COVID-19): A pooled analysis. Polish Arch Intern Med. 2020;130(4):304-309. doi:10.20452/pamw.15272

Wu C, Chen X, Cai Y, et al. Risk Factors Associated with Acute Respiratory Distress Syndrome and Death in Patients with Coronavirus Disease 2019 Pneumonia in Wuhan, China. JAMA Intern Med. 2020;180(7):934-943. doi:10.1001/jamainternmed.2020.0994

Liu W, Tao ZW, Wang L, et al. Analysis of factors associated with disease outcomes in hospitalized patients with 2019 novel coronavirus disease. Chin Med J (Engl). 2020;133(9):1032-1038. doi:10.1097/CM9.0000000000000775

Mehra MR, Desai SS, Kuy S, Henry TD, Patel AN. Cardiovascular Disease, Drug Therapy, and Mortality in Covid-19. N Engl J Med. 2020:1-8. doi:10.1056/nejmoa2007621

Reynolds HR, Adhikari S, Pulgarin C, et al. ReninAngiotensinAldosterone System Inhibitors and Risk of Covid-19. N Engl J Med. 2020:1-8. doi:10.1056/nejmoa2008975

Zhang P, Zhu L, Cai J, et al. Association of Inpatient Use of Angiotensin-Converting Enzyme Inhibitors and Angiotensin II Receptor Blockers with Mortality among Patients with Hypertension Hospitalized with COVID-19. Circ Res. 2020:1671-1681. doi:10.1161/CIRCRESAHA.120.317134

Mancia G, Rea F, Ludergnani M, Apolone G, Corrao G. ReninAngiotensinAldosterone System Blockers and the Risk of Covid-19. N Engl J Med. 2020:1-10. doi:10.1056/nejmoa2006923




DOI: https://doi.org/10.30596/jih.v1i2.4972

Refbacks

  • There are currently no refbacks.


 

Fakultas Kedokteran

Universitas Muhammadiyah Sumatera Utara
Jln.Gedung Arca No. 53 Medan 20217
Telp/HP/Whatsapp: +62 8112570085, +62 857-6248-0974
Website : http://jurnal.umsu.ac.id/index.php/JIH/index
Email : implementahusada@umsu.ac.id